Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
drug launch
Pharma
ARS inks ex-US licensing pact for Neffy worth up to $465M
ARS will receive up to $465 million in a new licensing pact with ALK-Abelló to sell its epinephrine nasal spray Neffy in certain ex-U.S. territories.
Fraiser Kansteiner
Nov 11, 2024 9:44am
Study says top launches were for drugs for untreated diseases
Nov 6, 2024 9:55am
Apellis' weak quarter could signal Syfovre 'nadir': analysts
Nov 5, 2024 3:41pm
Incyte wins injunction to block Sun's Leqselvi launch
Nov 4, 2024 10:01am
Biogen raises profit guidance as Leqembi's launch trudges on
Oct 30, 2024 12:30pm
Amgen gears up to launch Eylea biosim as Regeneron plots appeal
Oct 23, 2024 10:16am
